# Defining ctDNA Metrics in Posttransplant Lymphoproliferative Disorder (PTLD)

> **NCT06954805** · PHASE2 · RECRUITING · sponsor: **Jennifer Amengual** · enrollment: 30 (estimated)

## Conditions studied

- Lymphoma
- Lymphoma, B-Cell

## Interventions

- **DRUG:** Rituximab
- **DRUG:** Etoposide
- **DRUG:** Prednisone
- **DRUG:** Vincristine
- **DRUG:** Cyclophosphamide
- **DRUG:** Doxorubicin
- **DEVICE:** CAPP-seq

## Key facts

- **NCT ID:** NCT06954805
- **Lead sponsor:** Jennifer Amengual
- **Sponsor class:** OTHER
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** RECRUITING
- **Start date:** 2025-04-14
- **Primary completion:** 2027-04-14
- **Final completion:** 2028-04-14
- **Target enrollment:** 30 (ESTIMATED)
- **Last updated:** 2025-05-02

## Collaborators

- [object Object]

## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT06954805

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT06954805, "Defining ctDNA Metrics in Posttransplant Lymphoproliferative Disorder (PTLD)". Retrieved via AI Analytics 2026-06-24 from https://api.ai-analytics.org/clinical/NCT06954805. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*